Bone marrow-derived hematopoietic stem cells for treatment of sickle cell disease
The purpose of this study is to determine the safety and effectiveness of bone marrow-derived hematopoietic stem cell (BM-HSCs) transplantation, using bone marrow from unrelated donors, in children with severe sickle cell disease who receive a reduced intensity conditioning regimen before the transplantation.
Read More
No additional information regarding the therapeutic cells was provided by the sponsor.
Read More
Product Information for
Bone marrow-derived hematopoietic stem cells for treatment of sickle cell disease